Cancer

Cell culture and mouse studies suggest activating PP2A could help treat K-Ras (KRAS)-mutant lung cancer. In five KRAS-mutant human lung cancer cell lines, a previously reported PP2A activator decreased survival compared with no treatment. In three xenograft mouse models of KRAS-mutant lung adenocarcinoma and in one genetic mouse model of KRAS-mutant non-small cell lung cancer (NSCLC), the PP2A activator decreased tumor volume and increased tumor cell apoptosis compared with vehicle. Next steps include optimization of the PP2A activator...